Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05675761
Other study ID # Innovation-A
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 4, 2023
Est. completion date October 31, 2024

Study information

Verified date January 2023
Source Fuzhou General Hospital
Contact Zongyang Yu, Ph.D
Phone 13509327806
Email yuzy527@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a prospective, multicenter clinical study. It is intended to discuss the efficacy of starting Azovudine treatment as early as possible for all types of patients of COVID-19, the time of remission of specific symptoms, the proportion of patients with severe diseases, oxygen and conditions, and related adverse reactions, so as to understand the efficacy and safety of Azovudine treatment in all types of COVID-19, and provide real world data support for the treatment of the majority of COVID-19 patients.


Description:

1. To evaluate the clinical efficacy of Azovudine in the treatment of mild, moderate and severe COVID-19. 2. To explore the safety and adverse reactions of Azovudine in the whole population of COVID-19. 3. To explore the remission time of clinical symptoms, signs and images of patients with COVID-19 treated with Azovudine. 4. Explore the clinical guiding value of CORMB score.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Over 18 years old; 2. Respiratory tract samples (nasopharynx, oropharynx, lower respiratory tract [such as sputum]) collected within 96 hours before enrollment were confirmed to be SARS CoV-2 positive by RT-PCR virus molecular amplification; 3. At least one symptom or sign of COVID-19 (symptoms and signs related to COVID-19, including cough, expectoration, dyspnea, fever, chills, fatigue, muscle soreness, diarrhea, headache, sore throat, nasal congestion, runny nose, etc.); 4. Participants who meet one or more of the following requirements: from the first COVID-19 symptom to the first medication = 5 days; 5. Agree to observe contraceptive measures during the clinical trial; 6. Participants who understand and agree to follow the planned research procedures; 7. Provide follow-up information during the study; 8. Understand the study and be willing to sign the informed consent form. Exclusion Criteria: 1. Those who are known to be allergic to any component of the intervention preparation used in the test; 2. Patients with abnormal liver function test (alanine aminotransferase and /or glutamic oxaloacetic aminotransferase exceed the upper limit of normal value by 3 times, or total bilirubin exceeds the upper limit of normal value by 2 times); 3. Patients with a known history of liver disease (cirrhosis with ChildPugh grade B and C); 4. Congestive heart failure within 6 months (NYHA ¾ Grade), patients with untreated symptomatic arrhythmia or myocardial infarction history; 5. Individuals with malabsorption syndrome or other diseases affecting gastrointestinal absorption, and patients who need intravenous nutrition or cannot take orally or through nasogastric tube; 6. Participants who have received other SARS CoV-2 monoclonal antibody therapy or antiviral therapy (including research therapy); 7. Participants who received COVID-19 convalescent plasma therapy; 8. Patients receiving anti HIV treatment; 9. Participants who also participate in any other type of medical research or are considered to be scientifically or medically incompatible with this research; 10. Participants who have participated in the intervention clinical research in the past 30 days should pass 5 half lives or 30 days, whichever is longer, if the previous research intervention has a longer half life. 11. Researchers believe that the test will endanger any health and safety of participants; 12. Women who are pregnant, nursing or planning to be pregnant during the study period or men whose partners plan to be pregnant during the study period; 13. Unable to provide informed consent.Contacts and Locations.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azorubine
Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)

Locations

Country Name City State
China The 900th Hospital of the Joint Logistic Support Force, PLA Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fuzhou General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Continuous recovery time of clinical symptoms of Azovudine in the treatment of COVID-19 Continuous recovery time of clinical symptoms of Azovudine in the treatment of COVID-19 Day 1 to 28 days
Primary Safety evaluation results: for example, AE (adverse events) and SAE (serious adverse events) up to the 28th day Safety evaluation results: for example, AE (adverse events) and SAE (serious adverse events) up to the 28th dayof Novel Coronavirus Infection by the National Health Commission (Trial Version 9) The development from asymptomatic to mild/general-type The development from mild to general-type/severe type The development from general-type to severe/critical type The development from severe to critical type Up to 28 days
Secondary Evaluation of positive rate nucleic acid and /or antigen retest is positive within 28 days after negative conversion of nucleic acid and /or antigen Day 1 to 28 days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure